Program
Panzyga
Also written as “Panzyga, 10% Intravenous Solution”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Agammaglobulinemia · Polyneuropathies · Purpura, Thrombocytopenic, Idiopathic, led by Octapharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Octapharma | 52 open or running | phase 4since Mar 6, 2019 | Mar 6, 2019 | Dec 31, 2028phase 3 · NCT04929236 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2019First study: phase 4 study in Chronic Immune ThrombocytopeniaFirst studyNCT03866798 · 6 enrolled · United States
- Aug 4, 20202 phase 3 studiesNCT04502030, NCT04508530
- Jun 11, 2021Phase 3 study in Pediatric Chronic Inflammatory Demyelinating PolyneuropathyNCT04929236 · 30 planned · United States
- Sep 30, 2025Phase 3 study in AgammaglobulinemiaNCT07220915 · 360 planned · United States, Bulgaria, Czechia and more
Ahead
- Dec 31, 2028Primary completion: phase 3 study in Pediatric Chronic Inflammatory Demyelinating PolyneuropathyNCT04929236
- Dec 2029Primary completion: phase 3 study in AgammaglobulinemiaNCT07220915
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07220915Agammaglobulinemia · United States, Bulgaria, Czechia and more | 3 | Recruiting | Dec 2029 | 360 |
| NCT04929236Pediatric Chronic Inflammatory Demyelinating Polyneuropathy · United States | 3 | Recruiting | Dec 31, 2028 | 30 |
| NCT04508530Pediatric acute-onset neuropsychiatric syndrome · United States, Italy, Sweden | 3 | Completed | Aug 27, 2024 | 71 |
| NCT04502030Leukemia, Lymphocytic, Chronic, B-Cell · United States, Czechia, Denmark and more | 3 | Completed | Sep 19, 2025 | 247 |
| NCT03866798Chronic Immune Thrombocytopenia · United States | 4 | Terminated | Sep 19, 2023 | 6 |
How it is read
Names in the registry
- “Panzyga”, 4 entries
- “Panzyga, 10% Intravenous Solution”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Agammaglobulinemia, 1 study
- Polyneuropathies, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.